Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,996,409	$ 12,210,857
Investments available-for-sale, at fair value	3,566,628	0
Accounts receivable	1,131,980	1,421,695
Inventory, net	654,917	909,328
Prepaid expenses and other	837,170	1,109,571
Total current assets	9,187,104	15,651,451
Operating lease right-of-use assets	892,685	1,007,202
Property and equipment, net	528,527	598,006
Other non-current assets	257,312	520,996
Total assets	10,865,628	17,777,655
Current liabilities:
Accounts payable	1,097,538	1,157,449
Accrued liabilities	1,321,771	2,209,606
SVB Term Loan, net of discount and debt issuance costs	3,075,506	3,812,498
NuvoGen obligation - current	446,031	446,031
Operating lease liabilities - current	481,967	475,126
Other current liabilities	136,074	170,047
Total current liabilities	6,558,887	8,270,757
NuvoGen obligation - non-current, net of discount	3,370,279	3,519,058
Operating lease liabilities - non-current, net of discount	423,237	546,324
Other non-current liabilities	38,723	49,819
Total liabilities	10,391,126	12,385,958
Commitments and Contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.001 par value; 26,666,667 shares authorized at March31 2023 and December 31 2022 2214,077 shares issued and outstanding at March 31 2023 and 2,213,897 shares issued and outstanding at December 31, 2022	2,214	2,214
Additional paid-in-capital	235,450,053	235,314,311
Accumulated other comprehensive income	4,514	2,679
Accumulated deficit	(234,982,279)	(229,927,507)
Total stockholders’ equity	474,502	5,391,697
Total liabilities and stockholders' equity	$ 10,865,628	$ 17,777,655